Connect with others who understand.

  • Learn from expert-reviewed resources
  • Real advice from people who’ve been there
  • People who understand what you’re going through
Sign Up Log In
Powered By
Real members of MyMyelomaTeam have posted questions and answers that support our community guidelines, and should not be taken as medical advice. Looking for the latest medically reviewed content by doctors and experts? Visit our resource section.
A MyMyelomaTeam Member asked a question 💭
Lake Charles, LA

https://careinfo.mayoclinic.org/7AdvancesInCART...

7 Advances in CART-T Cell Therapy
7 Advances in CART-T Cell Therapy
July 4
 · 
Reactions
A MyMyelomaTeam Member

I know of a person who only had a 6 month Remission for getting Car-T and then he Relapsed. He was in his late 70s. He had a SCT 10 years prior and had remained on Maintenance until it failed and then went to the Car-T.

There’s a new Blood MRD 10 -6 Test called GenoPredicta. In addition to identifying if a person is in Complete Remission, it can Predict how well a Car-T or BiSpecifics Treatments are likely to Work or Fail.

For people considering either a Car-T or BiSpecifics, it’s worth getting this Blood Test prior to Treatment. GeonoPredicta is currently Free, when ordered through your Onc. The company is doing their Early Adoption Tests at No Cost to either the Patient, Onc or Insurance.

I just got this GenoPredicta Test to compare it to my clonoSEQ Blood MRD Test - though I have no plans to ever get a Car-T or BiSpecifics, it will be interesting to see what my Test Results say about these for me.

I am hoping that the GenoPredicta will provide me a Full Genome Genetics Mapping. If so, I imagine I’ll have plenty of interesting data to Research and Learn About - plenty of new Dots-to-Connect

July 4
A MyMyelomaTeam Member

Yes great idea and thank you for sharing!
I’ll check it out cause it would save a lot of time and money!

July 4
MyMyelomaTeam

The specific Mayo Clinic article you've linked to isn't something that can be accessed here, so those exact 7 advances can't be pulled up. However, here's what is known about the key advances in CAR-T cell therapy for myeloma:

There are currently two FDA-approved CAR-T therapies for myeloma:

- Abecma (ide-cel) – approved Show Full Answer

The specific Mayo Clinic article you've linked to isn't something that can be accessed here, so those exact 7 advances can't be pulled up. However, here's what is known about the key advances in CAR-T cell therapy for myeloma:

There are currently two FDA-approved CAR-T therapies for myeloma:

- Abecma (ide-cel) – approved in March 2021
- Carvykti (cilta-cel) – also FDA-approved

Both target a protein called BCMA, found on myeloma cells.

Key progress includes:

- Deep and long-lasting remissions, even after many prior treatments
- CAR-T cells can live in the body long-term, continuing to fight cancer
- Studies show up to 3 in 4 people experience reduced cancer signs
- 1 in 3 people achieve complete response
- Ongoing clinical trials are exploring new targets beyond BCMA
- Research into combining CAR-T with other medications
- Bispecific antibodies emerging as an alternative for those who aren't CAR-T candidates

It's worth visiting the Mayo Clinic link directly, or asking your care team about the latest advances specific to your situation.

July 4
A MyMyelomaTeam Member

Thanks Larry I am going to ask my Hematology about getting that test at my appointment in September 11

July 6
A MyMyelomaTeam Member

Thanks Lany and Angie Nixon.

July 5 (edited)

Related Questions

View All
A MyMyelomaTeam Member asked a question 💭
Yardley, PA

A MyMyelomaTeam Member asked a question 💭
Orange County, CA

A MyMyelomaTeam Member asked a question 💭
Dubuque, IA

Continue with Facebook
Continue with Google
By joining, you accept our Terms of Use, and acknowledge our collection, sharing, and use of your data in accordance with our Health Data and Privacy policies.
Already a member? Log In